- Home
- THO vs NUVL Comparison
THO vs NUVL Comparison
Compare THO & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THO
- NUVL
- Stock Information
- Founded
- THO 1980
- NUVL 2017
- Country
- THO United States
- NUVL United States
- Employees
- THO N/A
- NUVL N/A
- Industry
- THO Homebuilding
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- THO Industrials
- NUVL Health Care
- Exchange
- THO Nasdaq
- NUVL Nasdaq
- Market Cap
- THO 5.0B
- NUVL 5.8B
- IPO Year
- THO N/A
- NUVL 2021
- Fundamental
- Price
- THO $105.90
- NUVL $78.33
- Analyst Decision
- THO Hold
- NUVL Strong Buy
- Analyst Count
- THO 10
- NUVL 11
- Target Price
- THO $94.25
- NUVL $120.91
- AVG Volume (30 Days)
- THO 649.8K
- NUVL 411.6K
- Earning Date
- THO 09-24-2025
- NUVL 11-11-2025
- Dividend Yield
- THO 1.89%
- NUVL N/A
- EPS Growth
- THO N/A
- NUVL N/A
- EPS
- THO 4.17
- NUVL N/A
- Revenue
- THO $9,589,874,000.00
- NUVL N/A
- Revenue This Year
- THO N/A
- NUVL N/A
- Revenue Next Year
- THO $3.34
- NUVL N/A
- P/E Ratio
- THO $25.36
- NUVL N/A
- Revenue Growth
- THO N/A
- NUVL N/A
- 52 Week Low
- THO $63.16
- NUVL $55.54
- 52 Week High
- THO $118.85
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- THO 50.07
- NUVL 50.30
- Support Level
- THO $103.76
- NUVL $77.88
- Resistance Level
- THO $110.42
- NUVL $83.09
- Average True Range (ATR)
- THO 2.87
- NUVL 3.07
- MACD
- THO -1.17
- NUVL 0.25
- Stochastic Oscillator
- THO 19.94
- NUVL 45.22
About THO Thor Industries Inc.
Based in Elkhart, Indiana, Thor Industries manufactures Class A, Class B, and Class C motor homes along with travel trailers and fifth-wheel towables across about 35 brands. Through the acquisition of Erwin Hymer in 2019, the company expanded its geographic footprint and now produces various motorized and towable recreational vehicles for Europe, including motor caravans, camper vans, urban vehicles, caravans, and other RV-related products and services. The company has also begun generating revenue through aftermarket component parts via the acquisition of Airxcel in 2021; however, this is still a nascent part of the business as it accounts for less than 10% of total sales. In fiscal 2024, the company wholesaled 186,908 units and generated over $10 billion in revenue.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.